Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price dropped 9.4% on Monday . The stock traded as low as $4.53 and last traded at $4.53. Approximately 300 shares were traded during ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

This research provides a quantitative analysis of the fibroblast-to-myofibroblast transition (FMT), a critical process in ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of ...

MELBOURNE, Australia I 19, 2024 I Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its ...

Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation radiopharma imaging and therapy technology ...

Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with ...

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

NOVEL molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at ...

Pathology and radiology giant Sonic Healthcare (ASX:SHL) says it is emerging from its post-pandemic malaise, with revenue ...

FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods ...